Associate Vice President - Aging Research

Lilly•Indianapolis, IN
•$219,000 - $321,200

About The Position

The Associate Vice President, Aging, owns Lilly’s aging strategy within Mobility and Healthy Aging (MHA), a pillar of Cardiometabolic Research (CMR), and serves as its senior scientific voice internally and externally. The leader brings deep expertise in the biology of aging—including cellular senescence, proteostasis, mitochondrial dysfunction, chronic inflammation, and epigenetic and molecular measures of biological age—to decisions about mechanisms, patient populations and settings, organizational capabilities, and portfolio fit. The role is accountable for the scientific credibility of aging-directed targets and assets in the MHA portfolio, and for translating aging biology into medicines with definable patient populations and measurable endpoints. The leader works across bone, muscle, and joint biology to identify interventions that address aging biology while delivering functional benefits across tissues, and collaborates with scientists and leaders across Lilly on new approaches to aging and age-related disorders. The position leads aging science, strategy, and portfolio decisions; advises on biomarkers, models, assays, and translational tools; builds scientific capabilities and teams; represents Lilly in the aging research community; and supports external opportunities and collaborations. Up to 25% US/global travel is required.

Requirements

  • PhD or MD.
  • At least 10 years of experience in drug discovery and/or development in the pharmaceutical or biotechnology industry.
  • Recognized scientific expertise in the biology of aging, demonstrated by a substantial record of peer-reviewed publications, invited presentations, and standing in the aging research community.
  • Thorough understanding of drug discovery and development, including regulatory and intellectual property considerations, and a track record of contributions to INDs and/or NDAs.
  • Ability to think strategically across targets, patient populations, clinical development, and the regulatory environment.
  • Track record of leading, building, and developing scientific and/or project teams in an industry setting.
  • Ability to drive results in a fast-paced matrix environment, including newly formed organizations without established precedent or process.
  • Ability to translate dense scientific and clinical evidence into decision-grade recommendations for senior research and commercial leadership.
  • Excellent written and verbal communication skills.

Nice To Haves

  • Hands-on experience establishing, validating, and interpreting in vitro aging systems, including cellular senescence and stress-induced models, replicative aging, primary and iPSC-derived cells from aged or disease donors, organoid and co-culture systems, and omics-based aging signatures.
  • Hands-on experience with in vivo aging models, including naturally aged rodents, progeroid and genetic models, and diet- or injury-based models of age-related functional decline; ability to design studies accounting for age, sex, strain, cohort size, and duration, and interpret functional, histological, and molecular endpoints.
  • Ability to judge whether standard field readouts—including senescence markers, epigenetic age, lifespan, and healthspan measures—are decision-grade, and distinguish biomarkers of aging from biomarkers of mechanism or clinical benefit.
  • Ability to develop target-specific screening cascades and critical paths in aging, define go/no-go criteria, sequence in vitro and in vivo assays, select translatable pharmacodynamic markers, and build the data package to advance a target through candidate nomination and into the clinic.
  • Established external network across academic aging centers, geroscience consortia, and the longevity biotechnology ecosystem.
  • Experience with biomarker strategy and qualification, particularly measures of biological age or functional reserve.
  • Familiarity with the regulatory endpoint landscape for function and healthspan and the practical implications of surrogate endpoint qualification.
  • Passion for learning, openness to new opportunities, and entrepreneurial thinking.

Responsibilities

  • Own the scientific position of the Aging area, including target credibility, mechanisms, translational risk, and model strategy across internal programs and external opportunities.
  • Set and defend scientific criteria for aging-directed target entry and candidate selection, distinguishing well-supported mechanisms.
  • Serve as Lilly’s internal scientific authority on biological aging biomarkers, their validation status, and their practical use in development decisions.
  • Help build, lead, and develop a scientific team and shape the capabilities MHA needs in aging.
  • Partner with Bone, Muscle, and Joint leads and other Lilly therapeutic areas to connect aging mechanisms with tissue function and portfolio needs.
  • Ensure MHA has appropriate assays, models, and translational tools, assessing existing models and identifying needs for aged and functional in vivo systems or new capabilities.
  • Represent Lilly in aging biology and geroscience with key opinion leaders, academic centers, societies, and consortia.
  • Serve as an internal reference on aging science across Lilly for research and commercial leadership.
  • Lead and participate in advisory boards, scientific sessions, and external target reviews and diligence; help shape the field’s direction.
  • Build and sustain external scientific relationships, including across the longevity biotechnology and investment ecosystem.
  • Own and shape Lilly’s aging strategy within CMR, including positions on tissue and disease contexts that can convert aging mechanisms into approvable medicines and where Lilly should or should not participate.
  • Apply clinical and regulatory judgment to the fact that aging itself is not an approvable indication, beginning at target selection.
  • Set the scientific framework for external aging opportunities; define compelling opportunities, assess them, advise on portfolio fit, and support their integration into the portfolio.
  • Prepare teams for governance interactions and communicate strategy to senior management and cross-functional partners.
  • Serve on Joint Steering Committees or as a board observer to help shape the scientific direction of collaborations and new companies.
  • Travel up to 25% within the US and globally.

Benefits

  • Company bonus, depending in part on company and individual performance.
  • Eligibility to participate in a company-sponsored 401(k).
  • Pension.
  • Vacation benefits.
  • Eligibility for medical, dental, vision, and prescription drug benefits.
  • Flexible benefits, including healthcare and/or dependent day care flexible spending accounts.
  • Life insurance and death benefits.
  • Certain time-off and leave-of-absence benefits.
  • Well-being benefits, including an employee assistance program, fitness benefits, and employee clubs and activities.
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service